Regulatory Affairs Professionals Society· @RAPSorg · X·· 18 天前精选AI 评分58
AI 导读
美国卫生与公众服务部(HHS)宣布,不会对配制六种未获批肽类原料药(bulk drug substances)的州许可药房、联邦机构和持照医生采取执法行动。该表态划定了联邦执法在配制环节的适用范围。
推荐理由
HHS明确对六种未获批肽类原料药配制不予执法,读者可据此了解美国配制监管的边界调整。
正文
The Department of Health and Human Services has announced that it will not take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians that compound six unapproved peptide bulk drug substances.
https://hubs.la/Q04CSkrv0
来源:Regulatory Affairs Professionals Society · x.com